viewSeelos Therapeutics

Seelos Therapeutics stock doubles on license of potential Parkinson's candidate created at UCLA

Under the terms of the license, Seelos paid UCLA $100,000 upfront and will pay royalties on net sales

The New York-biotech focuses on developing technologies and therapeutics for the treatment of central nervous system and respiratory disorders

Seelos Therapeutics Inc (NASDAQ:SEEL) stock shot up Thursday after the biotech said it has exclusively in-licensed the rights to a potential disease modifying Parkinson’s disease therapy created by researchers at the University of California, Los Angeles (UCLA).

Parkinson’s disease is a progressive nervous system disorder that affects movement, and symptoms include tremors and changes in speech and gait.

Seelos Therapeutics stock nearly doubled to $3.30 in morning trade.

READ: Zynerba Pharmaceuticals launches Phase 2 trial of Zygel in autism spectrum disorder

The New York-based biotech has exclusively in-licensed the rights to a family of peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein).

The function of α-synuclein proteins in the healthy brain is unknown, but Parkinson's researchers are interested in it because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of the neurological disorder.

The company has designed the new program as SLS-007, with an initial focus on Parkinson's disease.

Pre-clinical data provides supportive evidence to slow progression, an early sign of disease-modifying potential in Parkinson’s disease.

Seelos will evaluate the potential for in-vivo delivery of SLS-007 in a Parkinson’s disease transgenic mice model.

"Accumulation and aggregation of α-synuclein is a pathological hallmark of Parkinson’s disease,” Seelos Therapeutics CEO Raj Mehra said in a statement. “Though its role is not completely understood, it appears pivotal in the pathogenesis of Parkinson’s and other α-synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. Reducing the levels of pathological forms of α-synuclein may alter the course of Parkinson’s."

Tim Whitaker, who is the head of R&D at Seelos, said that the current available treatments for Parkinson’s including Dopamine promoter Levodopa and deep brain stimulation, “long-term outcomes for patients remain poor."

"With no disease-modifying treatments, and long-term use of established dopaminergic therapies resulting in both adverse events and side effects, significant need remains to develop not only a better means of restoring striatal dopamine but a safe and effective treatment that slows progression of the disease in patients with Parkinson’s,” said Whitaker.

Under the terms of the license, Seelos paid The UC Regents and UCLA $100,000 upfront and will pay royalties on net sales.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 


Quick facts: Seelos Therapeutics

Price: 0.655 USD

Market: NASDAQ
Market Cap: $34.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...


2 min read